Parkinson disease (PD) is characterized by a clear beneficial motor response to levodopa (LD) treatment. However, with disease progression and longer LD exposure, drug-related motor fluctuations usually occur. Recognition of the individual relationship between LD concentration and its effect may be difficult, due to the complexity and variability of the mechanisms involved. This work proposes an innovative procedure for the automatic estimation of LD pharmacokinetics and pharmacodynamics parameters, by a biologically-inspired mathematical model. An original issue, compared with previous similar studies, is that the model comprises not only a compartmental description of LD pharmacokinetics in plasma and its effect on the striatal neurons, b...
International audienceBackground: Parkinson’s disease is the second most common neurodegenerative di...
Objective: Parameters of a pharmacokinetic-pharmacodynamic (PK-PD) model of levodopa have been claim...
International audienceBackground: Parkinson’s disease is the second most common neurodegenerative di...
Parkinson disease (PD) is characterized by a clear beneficial motor response to levodopa (LD) treatm...
Parkinson disease (PD) is characterized by a clear beneficial motor response to levodopa (LD) treatm...
Parkinson disease (PD) is characterized by a clear beneficial motor response to levodopa (LD) treatm...
Malfunctions in the neural circuitry of the basal ganglia (BG), induced by alterations in the dopami...
Malfunctions in the neural circuitry of the basal ganglia (BG), induced by alterations in the dopami...
Levodopa is considered the gold standard treatment of Parkinson’s disease. Although very effective i...
Levodopa is considered the gold standard treatment of Parkinson’s disease. Although very effective i...
The effect of levodopa in alleviating the symptoms of Parkinson's disease is altered in a highly non...
The effect of levodopa in alleviating the symptoms of Parkinson's disease is altered in a highly non...
A pharmacodynamic model is presented to describe the motor effects (tapping rate, Unified Parkinson’...
Objective: Parameters of a pharmacokinetic-pharmacodynamic (PK-PD) model of levodopa have been claim...
International audienceBackground: Parkinson’s disease is the second most common neurodegenerative di...
International audienceBackground: Parkinson’s disease is the second most common neurodegenerative di...
Objective: Parameters of a pharmacokinetic-pharmacodynamic (PK-PD) model of levodopa have been claim...
International audienceBackground: Parkinson’s disease is the second most common neurodegenerative di...
Parkinson disease (PD) is characterized by a clear beneficial motor response to levodopa (LD) treatm...
Parkinson disease (PD) is characterized by a clear beneficial motor response to levodopa (LD) treatm...
Parkinson disease (PD) is characterized by a clear beneficial motor response to levodopa (LD) treatm...
Malfunctions in the neural circuitry of the basal ganglia (BG), induced by alterations in the dopami...
Malfunctions in the neural circuitry of the basal ganglia (BG), induced by alterations in the dopami...
Levodopa is considered the gold standard treatment of Parkinson’s disease. Although very effective i...
Levodopa is considered the gold standard treatment of Parkinson’s disease. Although very effective i...
The effect of levodopa in alleviating the symptoms of Parkinson's disease is altered in a highly non...
The effect of levodopa in alleviating the symptoms of Parkinson's disease is altered in a highly non...
A pharmacodynamic model is presented to describe the motor effects (tapping rate, Unified Parkinson’...
Objective: Parameters of a pharmacokinetic-pharmacodynamic (PK-PD) model of levodopa have been claim...
International audienceBackground: Parkinson’s disease is the second most common neurodegenerative di...
International audienceBackground: Parkinson’s disease is the second most common neurodegenerative di...
Objective: Parameters of a pharmacokinetic-pharmacodynamic (PK-PD) model of levodopa have been claim...
International audienceBackground: Parkinson’s disease is the second most common neurodegenerative di...